{"product_id":"sxtp-five-forces","title":"(SXTP) 60 Degrees Pharmaceuticals, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis 60 Degrees Pharmaceuticals, Inc. Porter's Five Forces Analysis helps you assess rivalry, buyer and supplier power, substitutes, and new entrants to understand the company’s competitive position. This page shows a real preview of the actual report content, so you can review it before purchase. Buy the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive ingredient dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals is exposed to high supplier leverage because tafenoquine and other pipeline compounds likely come from a small set of specialized GMP suppliers. For a small specialty pharma company, even one API or excipient delay can push trial timelines and disrupt commercial supply. Exact specs, tight quality controls, and limited manufacturing slots make switching hard, so supplier power stays elevated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. depends on CROs, labs, and clinical sites to run Arakoda and pipeline studies, so suppliers hold real leverage. In FY2025, specialized infectious-disease trial work can command premium pricing because the vendor pool is narrow. Switching vendors is costly too, since it can trigger protocol transfer, data review, and revalidation delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing capacity constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. has limited scale, so if it outsources production, contract manufacturers can hold real leverage. Small-batch sterile and GMP capacity is tight in pharma, and bigger buyers usually get better pricing, faster slots, and more flexibility. When capacity is scarce, 60 Degrees Pharmaceuticals, Inc. can face higher unit costs, longer lead times, and weaker supply control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and licensing inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. depends on external IP such as the Tufts Medical Center license, so suppliers of patents and know-how can hold real leverage. Royalty and milestone terms can pressure margins, especially while the company is still scaling a narrow commercial base and funding development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal IP can limit pricing power\u003c\/li\u003e\n\u003cli\u003eRoyalties cut gross profit\u003c\/li\u003e\n\u003cli\u003eMilestones raise cash needs\u003c\/li\u003e\n\u003cli\u003eLicense terms can restrict flexibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory quality requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory quality rules narrow the supplier pool for 60 Degrees Pharmaceuticals, Inc.: only vendors that can prove FDA cGMP and global quality compliance can supply key inputs, so approved sources carry more leverage. Switching is slow and costly because each new supplier needs audits, validation, and documentation.\u003c\/p\u003e\n\u003cp\u003eThat raises bargaining power for compliant suppliers, while also limiting the Company’s ability to move to cheaper, higher-risk alternatives. In practice, this can lock in higher unit costs and longer lead times.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFewer FDA-qualified vendors\u003c\/li\u003e\n\u003cli\u003eHigher switching friction\u003c\/li\u003e\n\u003cli\u003eApproved suppliers gain pricing power\u003c\/li\u003e\n\u003cli\u003eRisky sourcing stays off-limits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e60 Degrees Pharma Faces High Supplier Leverage and Margin Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. faces high supplier power because it relies on a narrow set of GMP API, CRO, and licensed-IP providers. In small specialty pharma, even one qualified vendor change can delay FDA filings, trials, and product supply, while approved sources can charge more when capacity is tight.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/CRO scarcity\u003c\/td\u003e\n\u003ctd\u003eHigh leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching validation\u003c\/td\u003e\n\u003ctd\u003eCostly, slow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense terms\u003c\/td\u003e\n\u003ctd\u003eMargin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses 60 Degrees Pharmaceuticals, Inc.’s competitive pressures, supplier and buyer power, substitutes, and entry threats shaping profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA clear, one-sheet view of 60 Degrees Pharmaceuticals’ five forces—quickly revealing strategic pressure points and easing decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for 60 Degrees Pharmaceuticals, Inc., helping users verify key claims quickly and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayer sensitivity is high because 60 Degrees Pharmaceuticals, Inc. sells into a market driven by insurers, PBMs, and government buyers, not just patients. With one commercial product, ARAKODA, even small rebate or formulary demands can hit gross margin fast. In 2025, that buyer leverage can matter more than unit growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited product portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals’ customer power is high because it relies on one marketed product, Arakoda, so buyers can compare it directly with other malaria prophylaxis options if price is weak. A one-product portfolio also cuts cross-selling leverage, so the Company has less room to bundle or offset discount demands. Buyers can still press for proof of value before reimbursement or stocking, especially when they can choose among multiple alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescriber influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysicians and travel medicine specialists can sway demand because they choose the prophylaxis and treatment regimen. If efficacy, safety, and dosing are seen as close substitutes, prescribers hold more power; strong differentiation in outcomes or convenience cuts that power. 60 Degrees Pharmaceuticals reported 2025 revenue of $6.0 million, so each prescribing shift still matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstitutional purchasing channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals, clinics, and public health programs have strong bargaining power because they buy in volume and can push for better price and access terms. For 60 Degrees Pharmaceuticals, Inc., these buyers also expect dossiers, contracting, and clinical evidence before they add a product.\u003c\/p\u003e\n\u003cp\u003eThis makes institutional channels tough for small biotech firms, since one lost bid can delay revenue for months. In 2025, 60 Degrees Pharmaceuticals, Inc. still depended on narrow product demand, so each institutional customer could demand more proof for less price.\u003c\/p\u003e\n\u003cp\u003eThe result is high customer power: the buyer controls access, timing, and margin. Company Name has to spend more on evidence packages and sales support just to stay in the channel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVolume buyers press for discounts.\u003c\/li\u003e\n\u003cli\u003eProof and paperwork slow adoption.\u003c\/li\u003e\n\u003cli\u003eSmall biotech firms have weak leverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient urgency and unmet need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient urgency can reduce customer bargaining power for 60 Degrees Pharmaceuticals, Inc. When an infectious disease has few effective treatment or prevention options, buyers are less able to switch on price alone. That is strongest in niche or underserved indications where unmet need is high.\u003c\/p\u003e\n\u003cp\u003eFor travelers, military users, or patients facing malaria risk, the main decision driver is often access and timing, not just cost. So if 60 Degrees Pharmaceuticals, Inc. remains one of the few options in a narrow segment, customer pressure stays muted.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eFew alternatives limit price switching.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eUrgency raises value of access.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eUnderserved niches weaken buyer power.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Revenue, One Product: Customers Hold the Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer bargaining power is high for 60 Degrees Pharmaceuticals, Inc. because it depends on a single marketed product, ARAKODA, and 2025 revenue was only $6.0 million, so each payer or prescriber shift can move sales and margin fast. Institutional buyers and insurers can demand rebates, proof of value, and access terms before adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$6.0 million\u003c\/td\u003e\n\u003ctd\u003eLow scale, weak leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed products\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eHigh buyer power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e60 Degrees Pharmaceuticals, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact 60 Degrees Pharmaceuticals, Inc. Porter’s Five Forces Analysis you’ll receive after purchase—no placeholders, no edits, no surprises. You’re viewing the final, professionally formatted document, ready for immediate download and use. Once you complete your purchase, you’ll get instant access to this same file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty infectious disease niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. competes in a narrow but demanding infectious disease niche, where rivals can include big pharma, generics, and biotech firms chasing malaria or rare infections. Rivalry is driven less by brand and more by trial data, safety, and regulatory wins. WHO estimated 263 million malaria cases and 597,000 deaths in 2023, so clinical proof matters more than marketing in this space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-commercial-asset exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals relies on one approved commercial asset, Arakoda, so rivalry is highly concentrated in that therapy area. A new malaria prophylaxis or a better dosing regimen could cut share fast, especially because the company has only 1 core product to defend. That makes lifecycle management and label expansion critical to offset competitive pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePipeline rivalry is high because 60 Degrees Pharmaceuticals, Inc.'s Tafenoquine and Celgosivir compete with other repurposed and investigational drugs in COVID-19, babesiosis, dengue, and fungal disease, where clinical data are still thin. In early-stage markets, rival programs can pull the same investigators, patients, and investor capital before efficacy is proven. That makes claims noisy and raises the odds that a better-funded or faster-moving competitor captures attention first.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEvidence-driven differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn malaria prevention, 60 Degrees Pharmaceuticals, Inc. competes on trial data and safety: ARAKODA (tafenoquine) already has FDA approval, while WHO said malaria caused 263 million cases in 2023, so faster or broader efficacy data can quickly shift share.\u003c\/p\u003e\n\u003cp\u003eSafety and regulatory progress matter just as much; if a rival proves better tolerability or wins approvals sooner, pricing power and trial attention can weaken fast. Strong phase data can still give 60 Degrees Pharmaceuticals, Inc. a short moat in a crowded field.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA approval helps, but data wins.\u003c\/li\u003e\n\u003cli\u003eSafety can move adoption fast.\u003c\/li\u003e\n\u003cli\u003eBroader efficacy raises rivalry pressure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal and public health pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInfectious-disease work draws universities, public agencies, and nonprofits, so rivalry can stay high even when the commercial market is small. WHO estimated 263 million malaria cases and 597,000 deaths in 2023, which keeps R\u0026amp;D pressure intense and pulls multiple players into the same targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic funding can crowd in rivals\u003c\/li\u003e\n\u003cli\u003eUrgency speeds parallel development\u003c\/li\u003e\n\u003cli\u003eSmall markets still face heavy competition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor 60 Degrees Pharmaceuticals, Inc., that means competition is not just from drug makers, but from grant-backed programs and public health consortia that can move fast when outbreaks spike.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh malaria demand, fierce rivalry: 60 Degrees Pharmaceuticals faces intense competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for 60 Degrees Pharmaceuticals, Inc. because Arakoda is its only approved product and malaria rivals compete on trial data, safety, and speed to market. WHO estimated 263 million malaria cases and 597,000 deaths in 2023, so even small efficacy or tolerability gains can shift adoption fast. Public and grant-backed programs also keep pressure intense.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria cases\u003c\/td\u003e\n\u003ctd\u003e263 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria deaths\u003c\/td\u003e\n\u003ctd\u003e597,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore approved products\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative malaria prophylaxis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArakoda faces real substitution from doxycycline, atovaquone\/proguanil, mefloquine, and non-drug travel protocols. WHO said malaria still caused 263 million cases and 597,000 deaths in 2023, so travel doctors keep using familiar, low-cost options when they seem safer or easier. That keeps substitution pressure meaningful in prophylaxis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepurposed antivirals and anti-infectives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepurposed antivirals and anti-infectives can undercut Celgosivir and tafenoquine if older drugs show enough activity, especially when clinicians use off-label or emergency-use options during outbreaks. That risk is highest in fast-moving infections, where speed can matter more than a novel label. So 60 Degrees Pharmaceuticals, Inc. needs clear efficacy data and fast readouts to stand out.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-drug prevention measures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-drug prevention measures can lower demand for 60 Degrees Pharmaceuticals, Inc. products when vector avoidance, screening, isolation, or supportive care cut infection risk or symptom severity. These steps rarely replace medicine, but they can delay or reduce treatment use, especially in travel and outbreak settings. The threat is moderate because prevention works best before illness starts, while drugs still matter once infection is confirmed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric and low-cost options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneric antimalarials like doxycycline, mefloquine, and chloroquine keep price pressure high because payers can swap out premium branded drugs when older options fit the use case. WHO said malaria caused about 263 million cases and 597,000 deaths in 2023, so buyers still focus hard on cost and access. For 60 Degrees Pharmaceuticals, Inc., any premium must be backed by clear clinical value, not just branding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder generics cap pricing power.\u003c\/li\u003e\n\u003cli\u003ePayer pressure is strongest in malaria care.\u003c\/li\u003e\n\u003cli\u003eClinical benefit must justify premium use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWatchful waiting or supportive care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor 60 Degrees Pharmaceuticals, Inc., watchful waiting and supportive care are real substitutes when cases are mild or the diagnosis is still unclear. In more heterogeneous indications, clinicians can defer a branded therapy more easily, which raises substitution risk. That is especially true in emerging uses where treatment pathways are still not standardized.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupportive care can replace early drug use\u003c\/li\u003e\n\u003cli\u003eUnclear cases widen substitute choice\u003c\/li\u003e\n\u003cli\u003eNew indications face higher substitution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMalaria Prophylaxis Faces Strong Substitute Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is moderate to high for 60 Degrees Pharmaceuticals, Inc.: doxycycline, atovaquone\/proguanil, mefloquine, and non-drug prevention can replace Arakoda in travel care. WHO reported 263 million malaria cases and 597,000 deaths in 2023, but buyers still favor cheaper, familiar options when clinical value is unclear.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003ePressure\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoxycycline\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eLow-cost generic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtovaquone\/proguanil\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eFamiliar travel option\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-drug prevention\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eWHO 2023: 263M cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. faces a high bar because drug makers need FDA approval, multi-phase clinical trials, and strong safety data before launch. The cost and time burden is steep: the FDA approved 50 novel drugs in 2024, but only a small share of candidates ever reach that stage. In anti-infectives, proving efficacy is harder still, since patient pools are smaller and trials are tougher to run.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCapital intensity is a strong barrier for 60 Degrees Pharmaceuticals, because a single Phase 3 trial can cost tens of millions of dollars, and GMP manufacturing plus launch spend quickly add more. Small biotech firms can still enter, but they usually need venture capital or licensing partners to fund research, trials, and commercialization. That financing burden slows the pace of new entrants and keeps the threat moderate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific expertise requirement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty infectious-disease development needs deep skill in microbiology, clinical trial design, and regulatory strategy, so the entry bar is high. New firms without that know-how face a long learning curve and slower progress from lab work to approval. That helps niche players like 60 Degrees Pharmaceuticals, Inc. defend their position because expertise, not just capital, is the key scarce asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and data exclusivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. benefits from patent and regulatory exclusivity, which can delay direct copycats and lift entry costs. In the U.S., orphan drug exclusivity lasts 7 years and standard drug patents run 20 years from filing, so rivals often avoid exact clones and instead chase adjacent uses or improved formulations. Strong IP slows entry, but it does not stop it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents raise legal and R\u0026amp;D costs.\u003c\/li\u003e\n\u003cli\u003eExclusivity blocks direct imitation.\u003c\/li\u003e\n\u003cli\u003eEntrants may target niche variants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership-led entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor 60 Degrees Pharmaceuticals, Inc., partnership-led entry keeps the threat of new entrants moderate. New rivals can license assets, join academic collaborations, or in-license repurposed compounds, which is far cheaper than building a full R\u0026amp;D stack from scratch. In 2025, this is still easier in niche infectious diseases, where small, focused programs can reach trials without huge capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing lowers startup cost\u003c\/li\u003e\n\u003cli\u003eAcademic ties speed access\u003c\/li\u003e\n\u003cli\u003eRepurposed drugs cut risk\u003c\/li\u003e\n\u003cli\u003eThreat stays moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Entry Barriers Protect 60 Degrees Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for 60 Degrees Pharmaceuticals, Inc. is moderate. FDA drug approval, Phase 3 trial costs that can run tens of millions, and GMP scale-up make entry slow and expensive.\u003c\/p\u003e\n\u003cp\u003eIn 2024, the FDA approved 50 novel drugs, showing how few candidates clear the bar. Orphan drug exclusivity lasts 7 years, and standard patents run 20 years from filing, which further raises entry risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eFDA approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital\u003c\/td\u003e\n\u003ctd\u003eTens of millions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e7-20 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235022250249,"sku":"sxtp-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sxtp-five-forces.webp?v=1785733020","url":"https:\/\/dcfanalyst.com\/products\/sxtp-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}